Acronym
VAGABOND
Code
01IT3822
Duration
01 May 2024 → 30 April 2025
Funding
Regional and community funding: Special Research Fund
Promotor
Fellow
Research disciplines
-
Natural sciences
- Epigenetics
- Genome structure and regulation
- Cell death and senescence
- Cell division
- Cell growth and development
- Cell movement
- Cell signaling
- Cellular interactions and extracellular matrix
- Cytoskeleton
- Epigenetics
- Genetics
- Intracellular compartments and transport
- Membrane structure and transport
- Posttranslational modifications
- Transcription and translation
-
Medical and health sciences
- Epigenetics
- Transcription and translation
- Cancer biology
- Cancer therapy
- Oncology not elsewhere classified
- Cancer therapy
- Biomarker evaluation
- Biomarker discovery and evaluation not elsewhere classified
- Clinical trials
- Compound screening
- In vitro testing
- Non-clinical studies
- Cell death
- Cell division
- Cell growth and development
- Cell movement
- Cell signalling
- Cellular interactions and extracellular matrix
- Cytoskeleton
- Developmental biology
- Epigenetics
- Genetics
Keywords
high-throughput drugging
CDK12
combination drugging
novel treatment
precision oncology
Neuroblastoma
DNA damage
BRCA1
zebrafish xenograft
Replicative stress
Project description
High-risk neuroblastoma (HR-NB) patients undergo intensive multi-modal treatment, with over half succumbing to their disease. HR-NB cells exhibit replicative stress, and targeting DNA damage response (DDR) pathways represents a viable therapeutic option. Pharmalogical CDK12 inactivation leads to downregulation of DDR genes, selectively reducing viability of NB cells. A novel zebrafish HR-NB xenograft model for high-throughput compound testing is under development!